Globus Medical Inc. Class A Common Stock vs PPL Corporation Common Stock — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.99 (market cap $10.25B), while PPL Corporation Common Stock trades at $35.09 (market cap $26.15B). The key difference: PPL Corporation Common Stock is far larger — about 2.6× Globus Medical Inc. Class A Common Stock's market cap, and PPL Corporation Common Stock pays a 3.28% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and PPL Corporation Common Stock for 5 Days on average.
| GMED | PPL | |
|---|---|---|
Market Cap | $10.25B | $26.15B |
Volume | 1,059,528 | 5,207,054 |
Sector | Health | Utilities |
52-Week High | $96.82 | $39.81 |
52-Week Low | $58.33 | $31.97 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $9.76B | $46.14B |
Dividend Yield | — | 3.28% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
PPL Corporation trades at $34.63, up 0.84% with a bullish technical outlook supported by moving averages. The utility company shows solid fundamentals with $9.04B revenue, 13.47% net margin, and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $39.45 price target, representing 14% upside potential from current levels. Recent news highlights PPL's $23B infrastructure investment plan and focus on meeting rising electricity demand through strategic capacity expansion.
PPL presents a compelling investment case with strong analyst support, dividend growth potential, and strategic positioning in the growing utility sector. Key risks include execution challenges from the massive capital expenditure program, regulatory hurdles, and competitive pressures. The stock's current valuation at 20.49 P/E appears reasonable given the company's growth trajectory and defensive characteristics in the utility space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →PPL Corporation is a regulated utility holding company. Through its subsidiaries, it generates, transmits, distributes, and sells electricity and natural gas in Kentucky, Pennsylvania, and Rhode Island.
Read more on PPL →